Governor Kathleen Sebelius Nominated for Secretary of HHS - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Governor Kathleen Sebelius Nominated for Secretary of HHS


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Mar. 2, 2009, President Obama nominated Kansas Governor Kathleen Sebelius as his new Secretary of Health and Human Services (HHS). Sebelius, who has served as governor of Kansas since 2003, was Kansas’ Insurance Commissioner from 1994-2002. Sebelius, a Democrat governor in a predominately Republican state, is expected to help facilitate bipartisan healthcare reform. “As Secretary of Health and Human Services, Sebelius will work with Democrats and Republicans alike to cut costs, expand access, and improve the quality of healthcare for all Americans,” a White House press release states. Her nomination awaits Senate approval.

President Obama also appointed Nancy-Ann DeParle Counselor to the President and Director of the White House Office for Health Reform. DeParle was previously commissioner of Tennessee’s Department of Human Services. According to the White House press release, DeParle handled budget matters for federal healthcare programs during the Clinton administration and managed Medicare and Medicaid.

Obama stated in the release that, “Healthcare reform that reduces costs while expanding coverage is no longer just a dream we hope to achieve—it’s a necessity we have to achieve. And today, I am proud to announce key members of my team who will be critical to that effort: Kansas Governor Kathleen Sebelius for my Secretary of Health and Human Services and Nancy-Ann DeParle as Director of the White House Office for Health Reform.”

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
43%
Facility/environment problems
0%
Process development problems
0%
Production equipment downtime
14%
Raw material supply problems
14%
Regulatory restrictions
0%
Business decisions to limit production
29%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here